Clinical Trial Update: ISP-001: Sleeping Beauty Transposon-Engineered B Cells for MPS I [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for ISP-001, Immusoft's Sleeping Beauty transposon-engineered B cells intended to treat Mucopolysaccharidosis type I, currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucopolysaccharidosis Type

Drugs mentioned

• ISP-001 (Sleeping Beauty transposon-engineered B cells)

Snippet

Sponsor: Immusoft of CA, Inc. | Conditions: Mucopolysaccharidosis IH/S, Mucopolysaccharidosis IS | Phase 1 | Status: RECRUITING